Citi analyst Patrick B Donnelly has maintained their bullish stance on WST stock, giving a Buy rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Patrick B Donnelly has given his Buy rating due to a combination of factors, including management’s clear succession planning and the reaffirmation of medium‑term financial targets. He notes that the CEO’s retirement, while unexpected, is structured with a long lead time and continuity of leadership, which should help preserve strategic momentum and operational stability.
He also highlights that West Pharmaceutical has reiterated its 2026 outlook, calling for mid‑single‑digit organic revenue growth, meaningful margin expansion, and solid earnings progression. In his view, these fundamentals, combined with the anticipated orderly leadership transition, support a favorable risk‑reward profile and justify an expectation of strong share price appreciation from current levels.
In another report released yesterday, William Blair also assigned a Buy rating to the stock with a $248.06 price target.